LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber Sells 50,000 Shares

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 50,000 shares of LifeMD stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $7.55, for a total transaction of $377,500.00. Following the transaction, the chief executive officer now directly owns 2,653,715 shares in the company, valued at $20,035,548.25. This trade represents a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Justin Schreiber also recently made the following trade(s):

• On Thursday, January 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00.
• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total transaction of $163,000.00.

LifeMD Price Performance

NASDAQ:LFMD traded down $2.06 during trading hours on Friday, hitting $5.46. The company had a trading volume of 4,653,961 shares, compared to its average volume of 882,281. The company has a market capitalization of $236.47 million, a PE ratio of -8.53 and a beta of 1.50. The stock has a 50-day moving average price of $5.70 and a 200 day moving average price of $5.40. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $12.88.

Institutional Trading of LifeMD

A number of hedge funds have recently modified their holdings of LFMD. ProShare Advisors LLC bought a new stake in shares of LifeMD during the 4th quarter valued at $51,000. Oxford Asset Management LLP bought a new stake in shares of LifeMD during the 4th quarter valued at $52,000. Balyasny Asset Management L.P. bought a new stake in shares of LifeMD during the 4th quarter valued at $52,000. Intech Investment Management LLC bought a new stake in shares of LifeMD during the 3rd quarter valued at $54,000. Finally, AXQ Capital LP bought a new stake in shares of LifeMD during the 4th quarter valued at $57,000. Institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LFMD shares. KeyCorp decreased their target price on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Lake Street Capital initiated coverage on shares of LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of LifeMD in a report on Monday, November 11th. Finally, Mizuho initiated coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.